奥曲肽与垂体后叶素治疗肝硬化上消化道出血疗效比较探讨
|
摘要
目的对比探究奥曲肽与垂体后叶素治疗肝硬化上消化道出血的临床效果。方法选取该院在2017年6月—2018年10月收治的100例肝硬化上消化道出血患者,以双盲随机法分为对两组,每组50例;对照组应用垂体后叶素,观察组应用奥曲肽,对比两组治疗效果。结果①观察组的治疗总有效率为95.00%,显著高于对照组的78.00%(χ~2=11.259;P<0.05)。②观察组血红蛋白为(47.25±0.36)g/L,止血时间为(1.02±0.29)d,住院时间为(5.76±1.85)d;对照组血红蛋白为(35.60±0.72)g/L,止血时间为(2.03±0.51)d,住院时间为(8.40±2.47)d;由数据可知,经积极治疗后,在血红蛋白水平方面,观察组与对照组比较明显更高(t=10.250;P<0.05);观察组平均止血时间明显短于对照组(t=5.426;P<0.05);观察组住院时间则均明显要比对照组短(t=7.362;P<0.05)。③观察组的不良反应发生率为6.00%,显著低于对照组的24.00%(χ~2=12.285;P<0.05)。结论在肝硬化上消化道出血治疗中,奥曲肽的治疗效果及安全性均优于垂体后叶素,值得在推广应用。
Objective To compare the clinical effects of octreotide and pituitrin in the treatment of upper gastrointestinal hemorrhage due to cirrhosis. Methods 100 patients with cirrhosis of upper gastrointestinal hemorrhage admitted to our hospital from June 2017 to October 2018 were enrolled in a double-blind randomized method. The patients were divided into two groups, 50 case in each group. The control group was treated with pituitrin. The observation group used octreotide to compare the therapeutic effects of the two groups. Results 1.The total effective rate of the observation group was 95.00%, which was significantly higher than that of the control group 78.00%(χ~2=11.259; P<0.05). 2.The hemoglobin of the observation group was(47.25±0.36) g/L, the hemostasis time was(1.02±0.29) d, the hospitalization time was(5.76±1.85) d; the hemoglobin of the control group was(35.60±0.72) g/L, hemostasis time was(2.03±0.51)d,and the hospitalization time was(8.40±2.47)d. It can be seen from the data that after active treatment, the observation group was significantly higher than the control group in terms of hemoglobin level(t =10.250; P <0.05). The mean hemostasis time of the observation group was significantly shorter than that of the control group(t=5.426; P<0.05); the hospitalization time of the observation group was significantly shorter than the control group(t=7.362; P<0.05). 3.The incidence of adverse reactions in the observation group was 6.00%, which was significantly lower than 24.00% in the control group(χ~2=12.285; P<0.05). Conclusion In the treatment of upper gastrointestinal hemorrhage of cirrhosis, the therapeutic effect and safety of octreotide are better than that of pituitrin. It is worthy of popularization and application.
Objective To compare the clinical effects of octreotide and pituitrin in the treatment of upper gastrointestinal hemorrhage due to cirrhosis. Methods 100 patients with cirrhosis of upper gastrointestinal hemorrhage admitted to our hospital from June 2017 to October 2018 were enrolled in a double-blind randomized method. The patients were divided into two groups, 50 case in each group. The control group was treated with pituitrin. The observation group used octreotide to compare the therapeutic effects of the two groups. Results 1.The total effective rate of the observation group was 95.00%, which was significantly higher than that of the control group 78.00%(χ~2=11.259; P<0.05). 2.The hemoglobin of the observation group was(47.25±0.36) g/L, the hemostasis time was(1.02±0.29) d, the hospitalization time was(5.76±1.85) d; the hemoglobin of the control group was(35.60±0.72) g/L, hemostasis time was(2.03±0.51)d,and the hospitalization time was(8.40±2.47)d. It can be seen from the data that after active treatment, the observation group was significantly higher than the control group in terms of hemoglobin level(t =10.250; P <0.05). The mean hemostasis time of the observation group was significantly shorter than that of the control group(t=5.426; P<0.05); the hospitalization time of the observation group was significantly shorter than the control group(t=7.362; P<0.05). 3.The incidence of adverse reactions in the observation group was 6.00%, which was significantly lower than 24.00% in the control group(χ~2=12.285; P<0.05). Conclusion In the treatment of upper gastrointestinal hemorrhage of cirrhosis, the therapeutic effect and safety of octreotide are better than that of pituitrin. It is worthy of popularization and application.
引文
[1]张柱花.奥曲肽与垂体后叶素治疗肝硬化上消化道出血临床效果对比[J].临床合理用药杂志,2018,33(1):96-97.
[2]刘成吾.奥曲肽、垂体后叶素治疗肝硬化上消化道出血疗效对比评价[J].现代诊断与治疗,2017,22(23):72-73.
[3]高涛,高虹.奥曲肽与垂体后叶素治疗肝硬化上消化道出血的效果探究[J].中国医药指南,2018,11(4):157-158.
[4]戴木印,彭莉.奥曲肽与垂体后叶素治疗肝硬化上消化道出血的疗效及安全性研究[J].当代医学,2018,33(6)93-95.
[5]吕秀娜.奥曲肽、垂体后叶素治疗肝硬化上消化道出血的临床效果对比分析[J].中国医药指南,2018,34(24)49-50.
[6]朱成浩.肝硬化食管胃底静脉曲张破裂出血患者的诊治和预后分析[J].中国卫生标准管理,2016,33(15):71-72.
[7]邵春燕.奥曲肽联合埃索美拉唑治疗肝硬化上消化道出血的疗效观察[J].中外医学研究,2015(27):9-11.
[8]姜帆.奥曲肽联合埃索美拉唑治疗肝硬化上消化道出血的疗效观察[J].中国继续医学教育,2016,22(4):182-3183.
[2]刘成吾.奥曲肽、垂体后叶素治疗肝硬化上消化道出血疗效对比评价[J].现代诊断与治疗,2017,22(23):72-73.
[3]高涛,高虹.奥曲肽与垂体后叶素治疗肝硬化上消化道出血的效果探究[J].中国医药指南,2018,11(4):157-158.
[4]戴木印,彭莉.奥曲肽与垂体后叶素治疗肝硬化上消化道出血的疗效及安全性研究[J].当代医学,2018,33(6)93-95.
[5]吕秀娜.奥曲肽、垂体后叶素治疗肝硬化上消化道出血的临床效果对比分析[J].中国医药指南,2018,34(24)49-50.
[6]朱成浩.肝硬化食管胃底静脉曲张破裂出血患者的诊治和预后分析[J].中国卫生标准管理,2016,33(15):71-72.
[7]邵春燕.奥曲肽联合埃索美拉唑治疗肝硬化上消化道出血的疗效观察[J].中外医学研究,2015(27):9-11.
[8]姜帆.奥曲肽联合埃索美拉唑治疗肝硬化上消化道出血的疗效观察[J].中国继续医学教育,2016,22(4):182-3183.